Anti Angiogenic Temsirolimus(CCI-779, NSC 683864) CAS 162635-04-3

Over the years of experience in the industry, we are engaged in offering a rang of high quality Temsirolimus (CCI-779) CAS 162635-04-3. The alternative name of it can called CCI-779, sirolimus, NSC 683864 and Torisel which is a derivative and prodrug of rapamycin, a specific MTOR Inhibitor, and widely used in treating renal cell carcinoma (RCC). We used valuable raw material and adopt advanced technology to ensure its high purity and flawless quality. The Temsirolimus CAS NO 162635-04-3 have been commercialization productive. We keep certain inventory to meet clients requirement.

Thera. Category: Anti angiogenic

Cas No.: 162635-04-3

Synonym: TEMSIROLIMUS;CCL-779;Rapamycin 42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin;C15182;TeMsiroliMus (CCI-779, Torisel);rapaMycin 42-ester with 3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionic acid;TeMsiroliMus (Torisel)

Molecular Formula: C56H87NO16

Molecular Weight: 1030.29

Assay: ≥99.%

Packing: Export worthy packing

lMaterial Safety Data Sheet: Available on request

Usage:Temsirolimus (CCI-779) is an intravenous drug for the treatment of renal cell carcinoma (RCC), developed by Wyeth Pharmaceuticals and approved by the U.S. Food and Drug Administration (FDA) in late May 2007,[2] and was also approved by the European Medicines Agency (EMEA) on November 2007. It is a derivative and prodrug of sirolimus.

Product Categories : Inhibitors > MTOR Inhibitor